Lilly Oncology Medical (@LillyOncMed) “🩺SUNRAY 01 Part A | KRAS NSCLC Phase 3 Trial | Now Enrolling A phase 3 trial ev” — TopicDigg
Lilly Oncology Medical
@LillyOncMed
Dedicated to communicating the latest science & disease state education from Lilly Oncology. Intended for U.S. HCPs. Community Guidelines:
加入 March 2022
597 正在关注 6.6K 粉丝
🩺SUNRAY 01 Part A | KRAS NSCLC Phase 3 Trial | Now Enrolling
A phase 3 trial evaluating a targeted, PD 1 inhibitor–based approach in treatment naïve KRAS G12C mutant NSCLC.
Click below for trial details & enrollment info
显示更多
